Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NMRA Stock Forecast 2025-2026
$0.70
Current Price
$107.69M
Market Cap
Buy 3
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to NMRA Price Targets
+2,464.1%
To High Target of $18.00
+469.8%
To Median Target of $4.00
+42.5%
To Low Target of $1.00
NMRA Price Momentum
+6.1%
1 Week Change
+7.7%
1 Month Change
-92.8%
1 Year Change
-93.4%
Year-to-Date Change
-95.9%
From 52W High of $17.19
+14.9%
From 52W Low of $0.61
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Neumora (NMRA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NMRA and similar high-potential opportunities.
Latest NMRA Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, NMRA has a neutral consensus with a median price target of $4.00 (ranging from $1.00 to $18.00). The overall analyst rating is Buy (6.7/10). Currently trading at $0.70, the median forecast implies a 469.8% upside. This outlook is supported by 3 Buy, 5 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 2,464.1% upside. Conversely, the most conservative target is provided by Geoff Meacham at B of A Securities, suggesting a 42.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NMRA Analyst Ratings
3
Buy
5
Hold
1
Sell
NMRA Price Target Range
Low
$1.00
Average
$4.00
High
$18.00
Current: $0.70
Latest NMRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NMRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2025 | Needham | Ami Fadia | Buy | Reiterates | $5.00 |
| Apr 10, 2025 | Needham | Ami Fadia | Buy | Reiterates | $5.00 |
| Apr 2, 2025 | B of A Securities | Geoff Meacham | Underperform | Downgrade | $1.00 |
| Mar 10, 2025 | Guggenheim | Yatin Suneja | Neutral | Downgrade | $0.00 |
| Mar 7, 2025 | Stifel | Paul Matteis | Hold | Downgrade | $2.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $18.00 |
| Mar 4, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Reiterates | $4.00 |
| Mar 4, 2025 | Needham | Ami Fadia | Buy | Reiterates | $5.00 |
| Feb 14, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $30.00 |
| Jan 6, 2025 | B of A Securities | Geoff Meacham | Buy | Maintains | $7.00 |
| Jan 3, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $30.00 |
| Jan 2, 2025 | Needham | Ami Fadia | Buy | Reiterates | $23.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Nov 22, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $29.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $30.00 |
| Nov 13, 2024 | Needham | Ami Fadia | Buy | Reiterates | $23.00 |
| Nov 5, 2024 | JP Morgan | Tessa Romero | Neutral | Downgrade | $15.00 |
| Oct 18, 2024 | Needham | Ami Fadia | Buy | Reiterates | $23.00 |
| Oct 1, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Initiates | $30.00 |
Neumora Therapeutics Inc. (NMRA) Competitors
The following stocks are similar to Neumora based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neumora Therapeutics Inc. (NMRA) Financial Data
Neumora Therapeutics Inc. has a market capitalization of $107.69M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -79.0%.
Valuation Metrics
Market Cap
$107.69M
Enterprise Value
$-148,923,856
P/E Ratio
0.0x
PEG Ratio
-0.4x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+219.7%
Current Ratio
9.0x
Debt/Equity
0.4x
ROE
-79.0%
ROA
-48.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Neumora Therapeutics Inc. (NMRA) Business Model
About Neumora Therapeutics Inc.
What They Do
Develops precision medicines for neurological disorders.
Business Model
Neumora Therapeutics generates revenue by developing targeted therapies for neurological disorders, utilizing computational data science to understand disease biology and patient responses. Their focus on precision psychiatry aims to create tailored treatment options, which can lead to partnerships, licensing deals, and potential market sales of their innovative therapies.
Additional Information
The company is particularly focused on conditions such as depression and schizophrenia, and aims to improve treatment outcomes through a better understanding of patient subpopulations. This strategic focus on precision medicine positions Neumora Therapeutics as an attractive investment opportunity within the biotechnology sector, especially as mental health therapies gain increasing market attention.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
103
CEO
Mr. Henry O. Gosebruch
Country
United States
IPO Year
2023
Website
www.neumoratx.comNeumora Therapeutics Inc. (NMRA) Latest News & Analysis
Latest News
Quick Summary
Kuehn Law is investigating potential fiduciary breaches by Neumora Therapeutics' officers and directors related to misrepresentations in Phase Two and Three trial data for Navacaprant.
Why It Matters
Concerns over fiduciary breaches and misleading trial data can lead to legal repercussions and stock volatility for Neumora Therapeutics, affecting investor confidence and share prices.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Neumora Therapeutics, Inc. (NASDAQ: NMRA) will hold its Q1 2025 results conference call on May 12, 2025, at 4:30 PM ET, featuring key company executives and analysts.
Why It Matters
Neumora's upcoming Q1 2025 results conference call provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
5 days ago
Quick Summary
The company plans to report data on NMRA-511 for Alzheimer's agitation by late 2025 and anticipates results from major depressive disorder studies in 2026. It secured a $125 million debt facility, extending its cash runway to 2027.
Why It Matters
Upcoming data releases in Alzheimer's and major depressive disorder may impact stock volatility. Secured funding extends cash runway, indicating financial stability for ongoing projects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
19 days ago
Quick Summary
Neumora Therapeutics (Nasdaq: NMRA) will host a conference call and webcast on April 28, 2025, at 4:30 p.m. The company has seven brain disease programs, two of which are in clinical stages.
Why It Matters
Neumora Therapeutics' conference call may provide insights on its pipeline progress and clinical programs, which could influence investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Neumora Therapeutics, Inc. (NASDAQ: NMRA) and its officers, alleging violations of federal securities laws related to its September 2023 IPO.
Why It Matters
A class action lawsuit against Neumora Therapeutics over alleged securities law violations could impact the company's stock price and investor confidence, influencing market sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky, LLP has informed investors of a class action securities lawsuit against Neumora Therapeutics, Inc. (NASDAQ: NMRA).
Why It Matters
The class action lawsuit against Neumora Therapeutics could impact stock prices, investor sentiment, and the company's financial stability, prompting potential volatility in NMRA shares.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NMRA Stock
What is Neumora Therapeutics Inc.'s (NMRA) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Neumora Therapeutics Inc. (NMRA) has a median price target of $4.00. The highest price target is $18.00 and the lowest is $1.00.
Is NMRA stock a good investment in 2025?
According to current analyst ratings, NMRA has 3 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $0.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NMRA stock?
Wall Street analysts predict NMRA stock could reach $4.00 in the next 12 months. This represents a 469.8% increase from the current price of $0.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neumora Therapeutics Inc.'s business model?
Neumora Therapeutics generates revenue by developing targeted therapies for neurological disorders, utilizing computational data science to understand disease biology and patient responses. Their focus on precision psychiatry aims to create tailored treatment options, which can lead to partnerships, licensing deals, and potential market sales of their innovative therapies.
What is the highest forecasted price for NMRA Neumora Therapeutics Inc.?
The highest price target for NMRA is $18.00 from Douglas Tsao at HC Wainwright & Co., which represents a 2,464.1% increase from the current price of $0.70.
What is the lowest forecasted price for NMRA Neumora Therapeutics Inc.?
The lowest price target for NMRA is $1.00 from Geoff Meacham at B of A Securities, which represents a 42.5% increase from the current price of $0.70.
What is the overall NMRA consensus from analysts for Neumora Therapeutics Inc.?
The overall analyst consensus for NMRA is neutral. Out of 10 Wall Street analysts, 3 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $4.00.
How accurate are NMRA stock price projections?
Stock price projections, including those for Neumora Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 12:30 AM UTC